Company Profile

Third Wave Technologies Inc
Profile last edited on: 12/30/22      CAGE: 1NY17      UEI: S4LFLEK1BFC7

Business Identifier: Enzyme And Isoenzyme Diagnostic Agents
Year Founded
1992
First Award
1993
Latest Award
2004
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

502 South Rosa Road
Madison, WI 53719
   (608) 273-8933
   N/A
   www.twt.com
Location: Single
Congr. District: 02
County: Dane

Public Profile

In early June 2008, Third Wave Technologies was acquired by Hologic, Inc., of Bedford, MA. Operting as a wholly owned subsiduray of Hologic, Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. Hologic holds the number one position in nine technology areas serving woman's health, including breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing and osteoporosis detection. Hologic believes that the health issues facing women today deserve and demand the singular dedication of a passionate company.The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
150-249
Revenue Range
15M-20M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : TWTI
IP Holdings
150-249

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 2 NIH $1,208,626
Project Title: Genetic Profiles For Perioperative Applications
2002 1 NIH $100,000
Project Title: A HTS Gene Expression Assay for Screening Nutraceuticals
2001 2 NIH $849,595
Project Title: New Method For Direct And Quantitative RNA Detection
2001 2 NIH $637,430
Project Title: Low Cost HIV Drug Susceptibility Profiling
1999 1 NIH $100,000
Project Title: Low Cost HBV Drug Susceptibility Profiling

Key People / Management

  Kevin Conroy -- President and Chief Executive Officer

  Cindy S Ahn -- Vice President and General Counsel

  Maneesh Arora -- Chief Financial Officer

  John Bellano -- Vice President, Sales

  Maryann Brow

  Lance Fors

  Jorge A Garces -- Vice President, Product and Platform Development

  Rod Hise -- Vice President, Corporate Affairs

  Hon S Ip

  Robert W Kwiatkowski

  Bruce P Neri -- Sr Vice President

  D Michael Olive

  Marilyn C Olson

  John J Puisis

  Ivan Trifunovich -- Senior Vice President